Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06141668 · ClinicalTrials.gov registry record · NA
Optimal Stimulation Parameters to Disrupt Epileptiform Activity
A NA study of Refractory Epilepsy, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06141668 is a NA study of Refractory Epilepsy that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 30 participants, below the 61-participant average among 4 other Refractory Epilepsy trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06141668, a NA study of Refractory Epilepsy, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Open-loop electrical stimulation has been found to reduce spike activity and seizures, but determining the optimal parameters to achieve these effects requires a brute force trial-and-error approach that relies on subjective physician discretion. We will compare the performance of stimulation parameters identified in rodent models to the recommended parameters for neuromodulation used in clinical practice.
Conditions Studied
Interventions
- OTHER Neurostimulation
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-06-13 |
| Est. Completion | 2026-11-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06141668
The ClinicalTrials.gov registry entry for NCT06141668 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 61-participant average among 4 other Refractory Epilepsy trials with a reported enrollment target (51% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Refractory Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which Neurostimulation is the first listed.
NCT06141668 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06141668 about?
NCT06141668 is a clinical study titled "Optimal Stimulation Parameters to Disrupt Epileptiform Activity". Open-loop electrical stimulation has been found to reduce spike activity and seizures, but determining the optimal parameters to achieve these effects requires a brute force trial-and-error approach that relies on subjective physician discretion. We will compare the performance of stimulation parame...
What is the current status of trial NCT06141668?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2023-06-13. Estimated completion is 2026-11-30.
What conditions does trial NCT06141668 study?
This clinical trial studies the following conditions: Refractory Epilepsy.
What interventions are being tested in trial NCT06141668?
The interventions under investigation include: Neurostimulation (OTHER).
Who is sponsoring clinical trial NCT06141668?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06141668 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy
RECRUITING · NA
-
Self-administered ONe-of-a Kind Approach to Epilepsy Therapy Through a Web-based Music Application
RECRUITING · NA
-
The Efficacy of a Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy
RECRUITING · Phase 2
-
Optimization of Deep Brain Stimulation Parameters in Patients With Medically Refractory Epilepsy
RECRUITING · Early Phase 1
-
Safety and Efficacy of 333369 in the Treatment of Partial Epilepsy
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.